Abivax SA Sponsored ADR (ABVX)
NASDAQ:ABVX
Want to see ABVX full AI Analyst Report?
ABVX Stock Chart & Stats
$120.16
-$0.09(-1.29%)
At close: 4:00 PM EST
$120.16
-$0.09(-1.29%)
Day’s Range― - ―
52-Week Range$5.69 - $148.83
Previous CloseN/A
Volume62.24K
Average Volume (3M)2.14M
Market Cap
$7.86B
Enterprise Value$8.55B
Total Cash (Recent Filing)$530.16M
Total Debt (Recent Filing)$32.08M
Price to Earnings (P/E)―
Beta2.64
Next Earnings
Sep 21, 2026EPS Estimate
-0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.69
Shares Outstanding79,770,190
10 Day Avg. Volume4,423,772
30 Day Avg. Volume2,137,516
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)17.54
Price to Sales (P/S)0.00
P/FCF Ratio-51.21
Enterprise Value/Market Cap1.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-28.44
Forecast
1Y Price Target
$143.17Price Target Upside19.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.96
Revenue Forecast (FY)$81.52M
Bulls Say, Bears Say
Bulls Say
Strong Cash RunwayA cash balance near €492M and an indicated runway into Q4 2027 materially lowers near-term financing risk and supports completion of pivotal Phase 3 work and commercialization prep. This funding buffer gives management time to reach catalytic readouts without immediate dilution pressure.
De-levered Balance SheetA very low debt-to-equity ratio (~0.07) and expanded asset base provide financial flexibility and lower insolvency risk. Reduced leverage improves ability to absorb clinical setbacks, negotiate partnerships, and fund commercial builds without high interest burdens or restrictive covenants.
Durable Clinical Efficacy And Safety DataLong-term remission (week 144) and an absence of new safety signals strengthen obefazimod's clinical profile, lowering the probability of late-stage failure and improving the product's commercial and formulary prospects. Durable efficacy supports longer-term market adoption and payer negotiations.
Bears Say
No Current Product RevenueZero revenue underscores that Abivax remains fully pre-commercial and depends entirely on development financing. Without commercial sales, the company must continually access capital markets or partners to bridge development to launch, exposing shareholders to dilution and execution risk if milestones slip.
High And Persistent Cash BurnSustained operating and free cash outflows near -$156M annually create ongoing funding needs that will persist until revenue generation. Even with current runway, continued high burn raises the likelihood of future capital raises or strategic financing if timelines or costs expand.
Concentration On Single Pivotal ProgramBusiness outcomes are highly dependent on one late-stage asset and an imminent pivotal readout. A failed or delayed Phase 3 maintenance result would materially impair commercialization prospects, erode projected cash generation and force strategic pivots despite a currently strengthened balance sheet.
Abivax SA Sponsored ADR News
ABVX FAQ
What was Abivax SA Sponsored ADR’s price range in the past 12 months?
Abivax SA Sponsored ADR lowest stock price was $5.69 and its highest was $148.83 in the past 12 months.
What is Abivax SA Sponsored ADR’s market cap?
Abivax SA Sponsored ADR’s market cap is $7.86B.
When is Abivax SA Sponsored ADR’s upcoming earnings report date?
Abivax SA Sponsored ADR’s upcoming earnings report date is Sep 21, 2026 which is in 100 days.
How were Abivax SA Sponsored ADR’s earnings last quarter?
Abivax SA Sponsored ADR released its earnings results on May 22, 2026. The company reported -$0.708 earnings per share for the quarter, beating the consensus estimate of -$0.936 by $0.228.
Is Abivax SA Sponsored ADR overvalued?
According to Wall Street analysts Abivax SA Sponsored ADR’s price is currently Undervalued.
Does Abivax SA Sponsored ADR pay dividends?
Abivax SA Sponsored ADR does not currently pay dividends.
What is Abivax SA Sponsored ADR’s EPS estimate?
Abivax SA Sponsored ADR’s EPS estimate is -0.88.
How many shares outstanding does Abivax SA Sponsored ADR have?
Abivax SA Sponsored ADR has 79,770,190 shares outstanding.
What happened to Abivax SA Sponsored ADR’s price movement after its last earnings report?
Abivax SA Sponsored ADR reported an EPS of -$0.708 in its last earnings report, beating expectations of -$0.936. Following the earnings report the stock price went up 3.623%.
Which hedge fund is a major shareholder of Abivax SA Sponsored ADR?
Currently, no hedge funds are holding shares in ABVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abivax SA Sponsored ADR Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$143.17 (19.15% Upside)
$143.17 (19.15% Upside)
Blogger Sentiment
Bullish
ABVX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 487.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 12.8%
Last 30 Days ▲ 12.8%
News Sentiment
Bearish
Bullish news 33%
Bearish news 67%
Bearish news 67%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1259.43%
12-Months-Change
Fundamentals
Return on Equity
-165.19%
Trailing 12-Months
Asset Growth
249.60%
Trailing 12-Months
Company Description
Abivax SA Sponsored ADR
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
ABVX Stock 12 Month Forecast
Average Price Target
$143.17
▲(19.15% Upside)
Technical Analysis
Cytokinetics
―
Rhythm Pharmaceuticals
―
Legend Biotech
―
Atrium Therapeutics, Inc.
―
Nuvalent
―
Ownership Overview
―
Insiders
6.12% Mutual Funds
40.21% Other Institutional Investors
52.87% Public Companies and Individual Investors